Additional file 1: Table S1. of Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family

Intronic primers used to amplify coding exons of FGFR3 gene (Doxc). (DOCX 15 kb

Additional file 1: Table S1. of Identification and in silico characterization of a novel p.P208PfsX1 mutation in V-ATPase a3 subunit associated with autosomal recessive osteopetrosis in a Pakistani family

Intronic primers used to amplify coding exons of TCIRG1 gene; Table S2. Allele-specific PCR primers for c.624delC mutation in TCIRG1 gene; Table S3. Expected outcomes of allele-specific amplification; Table S4. Location of homozygous segments on genome shared by cases; Table S5. Known loci for osteopetrosis; Figure S1. Linked loci extracted by using Homozygosity mapper; Figure S2. Linked region at Chr11, showing TCIRG1 as candidate gene; Figure S3. Comparison of predicted secondary structure features for wild-type and mutant TCIRG1 protein. (DOCX 724 kb

An electrochemical sensor based on TiO₂/activated carbon nanocomposite modified screen printed electrode and its performance for phenolic compounds detection in water samples

<p>Herein, we reported a titanium oxide (TiO₂) modified activated carbon nanocomposite that showed advantageous characteristics in terms of electro-conductivity, catalytic activity and surface area. The designed nanocomposite was employed to modify the screen printed carbon electrode transducer surface in the construction of an electrochemical sensor. The electrode surface modification was characterised by cyclic voltammetry and impedimetric studies. The modified transducer surface was subsequently used for the detection of four phenolic endocrine disruptors, <i>p</i>-nitrophenol, hydroquinone, catechol and 1-naphtol. Under optimal conditions, TiO₂ modified activated carbon sensor was evaluated by differential pulse voltammetry showing a good linearity with correlation coefficients higher than 0.99. It showed, in parallel, a high sensitivity where the detection limits were 348 ng/L, 110.1 ng/L, 3.3 ng/L and 7.2 µg/L for the respective studied compounds (S/N = 3). Finally, we validated the method with river water samples, and good recovery values were obtained showing the potential application of the reported biosensor.</p

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

BackgroundTranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.MethodsWe did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.FindingsBetween July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).InterpretationWe found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.</div